Stay updated with breaking news from Full Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.
Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.
22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group...
Last month, for the first time ever, 3 people received compensation from the US government for the injuries ...
The Biden administration is in the process of finalizing a deal that would give the World Health Organization (WHO) ...